Andrew Stergachis
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (26)
Year:
2026
Kinetochores must accurately assemble on centromeres every cell cycle for faithful chromosome segregation. Although a conserved centromeric histone variant is essential for inner kinetochore formation, the budding yeast centromeric DNA is a poor template for nucleosome formation in vitro, possibly due to a resistance to bend. To better understand how the yeast inner kinetochore is assembled, we developed a one-step protocol to purify de novo assembled native inner kinetochore subcomplexes for structural studies. We performed cryoelectron microscopy on the purified complexes and generated medium to high resolution density maps of four separate inner kinetochore complexes, two of which had not previously been visualized. We detected differences between native and previously reconstituted structures, suggesting that the de novo assembly assay generated intermediate assemblage states. A strong extra structural density, which corresponds to an Ndc10 trimerization domain, associated with centromeric DNA and a pair of CBF3 complexes to induce significant centromere bending. Its deposition on the CBF3-CEN complex is essential for kinetochore assembly and chromosome segregation. We propose that Ndc10 trimerization facilitates bending of the centromeric DNA, leading to assembly and stabilization of the centromeric nucleosome and inner kinetochore.
Year:
2026
Structural variants (SVs) contribute substantially to genomic variation and disease, but detecting somatic SVs (sSVs) remains difficult due to reference bias, mosaicism, and enrichment in repetitive regions. Linear reference genomes, like GRCh38 and CHM13, do not fully capture individual genomic structure, which can obscure true somatic variation. Donor-specific assemblies (DSAs) generated from the same genome where sSVs are being assayed provide a personalized alternative, yet their performance for sSV detection has not been systematically assessed. As part of the Somatic Mosaicism across Human Tissues (SMaHT) Network, we benchmark a DSA for sSV discovery in the COLO829 melanoma cell line with a matched normal sample from the same individual. We compare sSV detection across GRCh38, CHM13, and the COLO829BL_DSA using three different sSV callers (Delly, Severus, and Sniffles2) and sequence data from multiple long-read platforms. The COLO829BL_DSA identifies 1.8-fold more manually validated sSVs than linear references, in regions both shared with GRCh38 and CHM13 and unique to the COLO829BL_DSA. Variants detected only with the COLO829BL_DSA are often found in satellite and other repeat-rich regions that are difficult to resolve using standard references. In addition, several COLO829BL_DSA-specific sSVs are located in genes, some of which are cancer associated. Overall, these results underscore the utility of DSAs in improving sSV detection.
Year:
2026
Over 90% of missense variants across ~4,000 disease-associated genes are variants of uncertain significance (VUS). Experimental variant effect measurements provide critical evidence about pathogenicity and inform disease biology, but most variants lack data and clinical translation has been limited. The Impact of Genomic Variation on Function Consortium generated experimental data for 62,215 variants across ten genes using multiplexed assays and 1,407 variants across 163 genes using arrayed assays, curated 193,139 additional community-generated variant effect measurements across 30 additional genes, and developed automated calibration methods for translating experimental data and variant effect predictions into clinical evidence. To reduce current VUS, we developed a scalable workflow using only experimental and predictive evidence, enabling reclassification of 75% of the 16,115 VUS in these genes as pathogenic or benign with 90,000 unobserved variants; 62% had enough evidence to be "preclassified" as pathogenic or benign. We validated our data, evidence and classifications using All of Us and created interactive resources to enable clinical use of the calibrated data. Thus, for 40 genes, representing 1% of the clinical genome, we resolve most existing VUS and future variants, illustrating how systematic use of scalable evidence can empower genomic medicine.
Year:
2026
Kinetochores must accurately assemble on centromeres every cell cycle for faithful chromosome segregation. Although a conserved centromeric histone variant is essential for inner kinetochore formation, the budding yeast centromeric DNA is a poor template for nucleosome formation in vitro , possibly due to a resistance to bend. To better understand how the yeast inner kinetochore is assembled, we developed a one-step protocol to purify de novo assembled native inner kinetochore subcomplexes for structural studies. We performed cryoelectron microscopy on the purified complexes and generated medium to high resolution density maps of four separate inner kinetochore complexes, two of which had not previously been visualized. We detected differences between native and previously reconstituted structures, suggesting that the de novo assembly assay generated intermediate assemblage states. A strong extra structural density, which corresponds to an Ndc10 trimerization domain, associated with centromeric DNA and a pair of CBF3 complexes to induce significant centromere bending. Its deposition on the CBF3-CEN complex is essential for kinetochore assembly and chromosome segregation. We propose that Ndc10 trimerization facilitates bending of the centromeric DNA, leading to assembly and stabilization of the centromeric nucleosome and inner kinetochore.
Year:
2026
Human neocentromeres are functional centromeres demarcated by CENP-A nucleosomes that form ectopically at alpha satellite-free loci. How neocentromeres reshape local chromatin and which features of native centromeric chromatin are preserved are unknown. We generated gapless, haplotype-resolved assemblies of native and neocentromeres from three patient-derived cell lines. Integrating CpG methylation, CENP-A profiling, and single-molecule chromatin fiber sequencing, we reveal chromatin features that define the essential centromeric architecture reconstituted during neocentromere establishment. We find that a deletion within the satellite array encompassing the hypo-CpG methylation centromere dip regions (CDRs) led to native centromere inactivation, that neocentromeres harbor CDRs and a dichromatin architecture, recapitulating features of alpha-satellite centromeres, and that LINEs demarcate neocentromere boundaries, implicating transposable elements in restricting CENP-A domain spreading. Moreover, neocentromeric chromatin is incompatible with promoter-like chromatin states, redefining the regulatory landscape within genic regions. Finally, using haplotype-specific chromatin footprinting, we resolve CENP-A nucleosome chromatin architecture of active centromeres.
Year:
2025
Background Advances in sequencing and standardized guidelines for variant classification have improved genetic diagnostics, but a large proportion of variants, particularly in genetically heterogeneous disorders such as hearing and vision loss, remain of uncertain significance. Although emerging multiplexed assays of variant effects (MAVEs) offer a solution to resolve these uncertainties, their integration into clinical practice in these fields remains constrained by limited familiarity and variable implementation among genetics professionals. Methods We conducted a survey of hearing and ocular genetics professionals ( n = 82) to explore their practices, experiences, and challenges in variant classification. The survey captured both quantitative and qualitative insights, allowing for an assessment of how experts engage with functional evidence and identifying patterns, perspectives, and areas for potential improvement in clinical workflows. Results Experts across hearing and vision loss genetics frequently encountered variants of uncertain significance (VUSs) and reported that functional data, while useful, often failed to resolve classification uncertainty due to both limited availability and variable quality of existing studies. Highest confidence was expressed in transcript assays and patient-derived cell models, as well as in computational predictors, while limited confidence or familiarity was reported for non-mammalian models and high-throughput experimental assays. Across both domains, respondents emphasized the need for improved data accessibility, standardized guidelines in the assessment of functional data for different genes or disease areas and expanded training to enhance the integration and clinical utility of functional evidence in variant classification. Conclusions Our survey identifies both common and domain-specific challenges in applying functional evidence for variant classification in hearing and ocular genetics, emphasizing the need for frameworks that account for biological complexity, methodological limitations, and barriers to data accessibility.
Year:
2025
Variants of uncertain significance (VUS) undermine genetic medicine implementation because they have an unknown relationship to disease and cannot be used for clinical decision-making. While evidence from multiplexed assays of variant effect (MAVEs) can help resolve VUS, major barriers prevent routine clinical use, including data fragmentation and assay calibration. To address these challenges, we present MaveMD (MAVEs for MeDicine), a new interface for the MaveDB database that displays clinical evidence calibrations, provides intuitive visualizations, integrates with ClinVar and ClinGen, and exports clinical evidence compatible with ACMG/AMP guidelines. MaveMD currently contains 476,076 variant effect measurements curated from 82 MAVE datasets spanning 39 disease-associated genes, enabling classification of 75% of ClinVar VUS and 62% of future variants in these genes. MaveMD is designed to support and facilitate future data generation efforts and the use of MAVE evidence in clinical practice, thereby reducing the VUS burden and improving genetic medicine outcomes.
Year:
2025
Identifying pathogenic non-coding variants that contribute to Mendelian conditions remains challenging as the functional impact of these variants on gene function is often unknown. We present IsoRanker, a long-read transcriptome sequencing-based framework that prioritizes functionally relevant non-coding variants by detecting genes and novel isoforms with outlier expression, allelic imbalance, and/or nonsense-mediated decay (NMD). We generated paired cycloheximide-treated and untreated fibroblast transcriptomes from 31 individuals (3 individuals with known transcript-altering rare variants and 28 individuals with unsolved conditions) and linked transcripts to phased long-read genomes. IsoRanker successfully recovered known transcript alterations in this cohort and remained robust in subsampling analyses to cohorts of 11 individuals and ∼5 million full-length transcripts per individual. However, performance was dependent upon de novo isoform caller choice, particularly for NMD-sensitive and novel isoforms. Among 28 previously unsolved cases, IsoRanker deprioritized most fibroblast-expressed candidate splice site variants while nominating new leads. In one individual, IsoRanker prioritized HARS1 , revealing biallelic non-coding variants that together produced a partial HARS1 loss-of-function and informed targeted therapy in this individual using histidine supplementation. These findings establish long-read, NMD-aware transcriptomics with IsoRanker as an effective approach for generating isoform-level functional evidence, improving classification of non-coding variants and supporting the diagnosis of individuals with rare diseases.
Year:
2025
Mosaic mutations in normal tissues occur at low variant allele fractions (VAFs), complicating detection. To benchmark strategies, the SMaHT Network created a cell-line mixture (1:49) and produced ultra-deep whole-genome sequencing using short and long reads (five centers, 180–500× each). We assembled a reference of 44,008 mosaic SNVs and 2,059 Indels, cross-validation between platforms to expose limits of short-read analysis. We also partitioned the genome by mappability to examine the impact of genomic context, added a negative reference set, and accounted for culture-derived mutations. When seven institutions applied eleven algorithms to mixture data, call sets were largely discordant across tools and replicates, partly reflecting stochastic presence of low-VAF mutations in biological replicants. For >2% VAF SNVs, sensitivity and precision approached ∼80% at ≥300×, with little gain from additional sequencing. This work provides a comprehensive framework for reliable detection of low-VAF mutations in non-cancer tissues and a valuable resource for the community.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Collaborators (57)
richard james
Associate Professor
University of Washington
Robert Fulton
Assistant Professor
Washington University in St. Louis
Yoo-Jin Ha
Assistant Professor
Hanyang University
David Gilbert
Professor
San Diego Biomedical Research Institute
Chia-Lin Wei
Professor & Director
University of Washington
Mitchell Vollger
Assistant Professor
University of Utah
Ben Mallory
University of Washington
James Bennett
Principal Investigator
Seattle Children's Research Institute
Susan Biggins
Fred Hutchinson Cancer Research Center
Peter Park
Harvard University
Lea Starita
Research Assistant Professor
University of Washington
Andre Lieber
Professor
University of Washington
Jessica Ewald
Group Leader
European Bioinformatics Institute
Robert D. Steiner
University of Wisconsin School of Medicine and Public Health
Richard Stefan Isaac
Assistant Professor
Boston University
Lilia Iakoucheva
Professor
University of California, San Diego
Thomas A. Reh
Professor
University of Washington
Bluma J Lesch
Associate Professor
Yale University
Josh T Cuperus
University of Washington
Nicole Tillquist
Research Associate 1
University of Connecticut
Barbara Vona
Broad Institute
esteban miglietta
Broad Institute
Ting Wang
Washington University School of Medicine
Anne Carpenter
Institute Scientist and Senior Director
Broad Institute
Takayo Sasaki
Senior Staff Scientist
San Diego Biomedical Research Institute
Steven Henikoff
Fred Hutchinson Cancer Research Center
Evan Eichler
Howard Hughes Medical Institute
Mikko Taipale
Professor
University of Toronto
Shantanu Singh
Broad Institute
Benjamin Hitz
Stanford University
Beth Cimini
Associate Director, Bioimage Analysis
Broad Institute
Zhi Yu
Broad Institute
Julia Markowski
University of Potsdam
Predrag Radivojac
Northeastern University
Runxi Shen
Research Assistant Professor
Purdue University
Brian H. Shirts
Vanderbilt University Medical Center
Glennis Logsdon
Assistant Professor
University of Pennsylvania
yasuhiro arimura
Assistant professor
Fred Hutch Cancer Center
harshavardhan doddapaneni
Associate Professor
Baylor College of Medicine
Frederick Roth
Professor and Chair
University of Pittsburgh
Alan Beggs
Sir Edwin & Lady Manton Professor
Harvard Medical School
Christine Queitsch
Professor
University of Washington
Rachel J. O’Neill
University of Connecticut
Ahmad Abou Tayoun
mohammed bin rashid university of medicine and health sciences
Jessica Chong
University of Washington
Derek Janssens
Assistant Professor
Van Andel Institute
Elizabeth Blue
Professor
University of Washington
Tim Beißbarth
Head of department
Universitätsmedizin Göttingen
Tim Coorens
Research Group Leader
European Bioinformatics Institute
Nicolas Altemose
Assistant Professor
Stanford University
Stirling Churchman
Harvard University
Douglas Fowler
Professor
University of Washington
Daofeng Li
Assistant Professor
Washington University in St. Louis
Jill Johnsen
Professor
University of Washington
Alan Rubin
Group Leader
University of Melbourne
Christopher Mason
Professor
Weill Cornell Medical College
Anne O'Donnell-Luria
Associate Professor
Boston Children's Hospital
Make your next move.
Prepare your application
Review drafts before you send them.